Pedroza-Saavedra Adolfo, Rodriguez-Ocampo Angelica Nallelhy, Salazar-Piña Azucena, Perez-Morales Aislinn Citlali, Chihu-Amparan Lilia, Maldonado-Gama Minerva, Cruz-Valdez Aurelio, Esquivel-Guadarrama Fernando, Gutierrez-Xicotencatl Lourdes
Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.
Unidad Académica Químico Biológicas y Ciencias Farmacéuticas, Universidad Autónoma de Nayarit, 36715 Tepic, Mexico.
Vaccines (Basel). 2021 May 2;9(5):442. doi: 10.3390/vaccines9050442.
Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women. In this study, serum antibodies against conformational (VLPs) and linear epitopes of HPV16/18 L1 protein were assessed to distinguish HPV-vaccinated women from those naturally infected or those with uterine cervical lesions. The VLPs-16/18 were generated in baculovirus, and L1 proteins were obtained from denatured VLPs. Serum antibodies against VLPs and L1 proteins were evaluated by ELISA. The ELISA-VLPs and ELISA-L1 16/18 assays were validated with a vaccinated women group by ROC analysis and the regression analysis to distinguish the different populations of female patients. The anti-VLPs-16/18 and anti-L1-16/18 antibodies effectively detect vaccinated women (AUC = 1.0/0.79, and 0.94/0.84, respectively). The regression analysis showed that anti-VLPs-16/18 and anti-L1-16/18 antibodies were associated with the vaccinated group (OR = 2.11 × 10/16.50 and 536.0/49.2, respectively). However, only the anti-L1-16 antibodies were associated with the high-grade lesions and cervical cancer (CIN3/CC) group (OR = 12.18). In conclusion, our results suggest that anti-VLPs-16/18 antibodies are effective and type-specific to detect HPV-vaccinated women, but anti-L1-16 antibodies better differentiate the CIN3/CC group. However, a larger population study is needed to validate these results.
抗人乳头瘤病毒（HPV）L1蛋白的抗体与既往感染相关，并与疾病的进展有关，而抗L1病毒样颗粒（VLP）的抗体则用于追踪接种疫苗女性的中和抗体反应。在本研究中，评估了针对HPV16/18 L1蛋白构象（VLP）和线性表位的血清抗体，以区分接种HPV疫苗的女性与自然感染或患有子宫颈病变的女性。VLP-16/18在杆状病毒中产生，L1蛋白从变性VLP中获得。通过酶联免疫吸附测定（ELISA）评估针对VLP和L1蛋白的血清抗体。通过ROC分析和回归分析，在一组接种疫苗的女性中验证了ELISA-VLP和ELISA-L1 16/18检测方法，以区分不同人群的女性患者。抗VLP-16/18和抗L1-16/18抗体能有效检测出接种疫苗的女性（AUC分别为1.0/0.79和0.94/0.84）。回归分析表明，抗VLP-16/18和抗L1-16/18抗体与接种疫苗组相关（OR分别为2.11×10/16.50和536.0/49.2）。然而，只有抗L1-16抗体与高级别病变和宫颈癌（CIN3/CC）组相关（OR = 12.18）。总之，我们的结果表明，抗VLP-16/18抗体对于检测接种HPV疫苗的女性是有效且具有型特异性的，但抗L1-16抗体能更好地区分CIN3/CC组。然而，需要更大规模的人群研究来验证这些结果。
